Rituximab biosimilar (Boehringer Ingelheim)

利妥昔单抗生物类似药 (Boehringer Ingelheim)

Report date: 2026/03/23 20:03:44

Base Information

Drug NameRituximab biosimilar (Boehringer Ingelheim)
Drug Alias Name利妥昔单抗生物仿制药 (Boehringer Ingelheim)BI-695500
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLymphoproliferative DisordersAnemia +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[26] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesWake Forest University Health SciencesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgRutgers University
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmAnemiaHematologic Neoplasms +[16] 
Inactive IndicationsLymphoproliferative DisordersArthritis, RheumatoidLymphoma, T-Cell +[7] 

Other Information

ATC CodeL01XC02
Related LinksN/A